Work

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Year: 2016

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw227

Authors: M.E. Lacouture, D.M. Keefe, S. Sonis, A. Jatoi, D. Gernhardt, T. Wang, J.P. Doherty, N. Giri, S. Nadanaciva, J. O'Connell, E. Sbar, B. Piperdi, E.B. Garon

Institutions: Memorial Sloan Kettering Cancer Center, Royal Adelaide Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Mayo Clinic, Pfizer (United States), Albert Einstein College of Medicine, Montefiore Medical Center, University of California, Los Angeles

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2409547711

FWCI: 7.856

Cites: 9

Cited by: 67

Related to: 10